SEC Form 4 · accession 0001209191-17-054041
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Louis G Lange
Director
Period of report
Sep 25, 2017
Accepted (ET)
Sep 26, 2017 · 5:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 25, 2017 | S | 7,406 | $27.8482 | D | 453,393 | D | |
| Common StockF3 | Sep 25, 2017 | S | 7,594 | $28.7632 | D | 445,799 | D | |
| Common StockF4,F5 | Sep 25, 2017 | S | 600 | $27.9933 | D | 13,955 | I | By Adrienne M. MacMillan Revocable Trust |
| Common StockF6,F5 | Sep 25, 2017 | S | 400 | $28.8874 | D | 13,555 | I | By Adrienne M. MacMillan Revocable Trust |
| Common StockF7,F8 | Sep 25, 2017 | S | 636 | $28.0607 | D | 25,042 | I | By Amygdala Lange Trust |
| Common StockF9,F8 | Sep 25, 2017 | S | 364 | $28.8478 | D | 24,678 | I | By Amygdala Lange Trust |
| Common StockF10,F11 | Sep 25, 2017 | S | 641 | $28.0664 | D | 7,917 | I | By Lange Minors' Trust |
| Common StockF12,F11 | Sep 25, 2017 | S | 359 | $28.8757 | D | 7,558 | I | By Lange Minors' Trust |
| Common StockF13 | holding | — | — | — | 87,343 | I | By Asset Management Ventures Fund, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F10Represents the average weighted sale price. The lowest price at which shares were sold was $27.60 and the highest price at which shares were sold was $28.49.
- F11The reporting person's domestic partner is the trustee of the Lange Minors' Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- F12Represents the average weighted sale price. The lowest price at which shares were sold was $28.82 and the highest price at which shares were sold was $28.96.
- F13The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F2Represents the weighted average sale price. The lowest price at which shares were sold was $27.28 and the highest price at which shares were sold was $28.27. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6), (7), (9), (10) and (12) to this Form 4.
- F3Represents the average weighted sale price. The lowest price at which shares were sold was $28.30 and the highest price at which shares were sold was $29.04.
- F4Represents the average weighted sale price. The lowest price at which shares were sold was $27.75 and the highest price at which shares were sold was $28.50.
- F5The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- F6Represents the average weighted sale price. The lowest price at which shares were sold was $28.80 and the highest price at which shares were sold was $29.03.
- F7Represents the average weighted sale price. The lowest price at which shares were sold was $27.60 and the highest price at which shares were sold was $28.49.
- F8The reporting person's domestic partner is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- F9Represents the average weighted sale price. The lowest price at which shares were sold was $28.75 and the highest price at which shares were sold was $28.96.